DRUGapproved
Trametinib
Mechanism
For BRAF V600E (with dabrafenib). Tumor-agnostic approval.
Related claims (5)
| Type | Predicate | Conf | Source |
|---|---|---|---|
| drug efficacy | Dabrafenib plus trametinib has shown remarkable results in biliary tract cancers (BTC) as a second-line option for BRAF V600E-mutant BTC (clinical trial result). | 90% | 41646490 |
| drug efficacy | Phase 2 trials showed efficacy of dabrafenib + trametinib for patients with BRAF<sup>V600E</sup> mutations (clinical trial result). | 80% | 41060610 |
| drug efficacy | Dabrafenib + trametinib showed efficacy in patients with BRAF V600E mutations (clinical trial result) | 80% | 41060610 |
| drug efficacy | Phase 2 trials showed efficacy of dabrafenib + trametinib for patients with BRAF<sup>V600E</sup> mutations (clinical trial result). | 70% | 41060610 |
| drug efficacy | Phase 2 trials showed efficacy of dabrafenib + trametinib for patients with BRAF<sup>V600E</sup> mutations (clinical trial result). | 70% | 41060610 |
Off-Target Findings (0)
No Boltz-2 / Chai-1 off-target panel claims recorded for this drug.